睿知中国医院研究地图
候选清单

正在招募食管鳞状细胞癌肝细胞癌胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌和肝细胞癌和胃癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
  2. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  3. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05208762,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types

    入选标准第 2 条

    Participants with HNSCC must have histologically or cytologically-confirmed HNSCC

    入选标准第 12 条

    Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.

    入选标准第 14 条

    Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC

    入选标准第 23 条

  3. And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment

    排除标准第 5 条

    Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.

    排除标准第 7 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

    入选标准第 27 条

  5. Measurable disease per RECIST v1.1 at baseline

    入选标准第 28 条

  6. History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.

    排除标准第 1 条

    Pre-existing neuropathy ≥Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05208762,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Parts A and B:
  2. Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types
  3. Non-small cell lung cancer (NSCLC)
  4. Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)
  5. Esophageal squamous cell carcinoma (SCC)
  6. Triple negative breast cancer (TNBC)
  7. Participants must have disease that is relapsed or refractory, that has progressed on approved therapies, be intolerant to or refused such therapies, or such and therapies are contraindicated and in the judgement of the investigator, should have no appropriate SoC therapeutic option
  8. Participants must have PD-L1 expression based on historical testing
  9. Part C:
  10. Participants must have disease that is relapsed or refractory or be intolerant to SoC therapies and must have one of the following tumor types
  11. HNSCC
  12. Participants with HNSCC must have histologically or cytologically-confirmed HNSCC
  13. NSCLC
  14. Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.
  15. Esophageal SCC
  16. Pancreatic cancer
  17. Hepatocellular carcinoma
  18. TNBC
  19. Gastric cancer
  20. Endometrial cancer
  21. Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression ≥1 or <1 by CPS or TPS based on historical testing
  22. Part D and Part E:
  23. Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC
  24. Participants must have PD-L1 expression based on historical testing
  25. Participants with NSCLC; PD-L1 expression ≥ 1% by TPS
  26. Participants with HNSCC; PD--L1 expression ≥1 by CPS
  27. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  28. Measurable disease per RECIST v1.1 at baseline

排除标准:Exclusion Criteria:

  1. History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.
  2. Known active central nervous system metastases. Participants with previously-treated brain metastases may participate provided they:
  3. Are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment
  4. Have no new or enlarging brain metastases
  5. And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment
  6. Lepto-meningeal disease
  7. Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.
  8. Previous receipt of an monomethylauristatin E (MMAE)-containing agent.
  9. Pre-existing neuropathy ≥Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

引自 ClinicalTrials.gov, NCT05208762, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05208762,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05208762